astrazeneca uk limited
astrazeneca uk limited Company Information
Company Number
03674842
Next Accounts
Sep 2025
Shareholders
astrazeneca intermediate holdings limited
astrazeneca plc
Group Structure
View All
Industry
Activities of head offices
Registered Address
1 francis crick avenue, cambridge biomedical campus, cambridge, CB2 0AA
Website
www.astrazeneca.co.ukastrazeneca uk limited Estimated Valuation
Pomanda estimates the enterprise value of ASTRAZENECA UK LIMITED at £19.1b based on a Turnover of £14.4b and 1.32x industry multiple (adjusted for size and gross margin).
astrazeneca uk limited Estimated Valuation
Pomanda estimates the enterprise value of ASTRAZENECA UK LIMITED at £13b based on an EBITDA of £1.2b and a 10.47x industry multiple (adjusted for size and gross margin).
astrazeneca uk limited Estimated Valuation
Pomanda estimates the enterprise value of ASTRAZENECA UK LIMITED at £32.1b based on Net Assets of £15.2b and 2.11x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Astrazeneca Uk Limited Overview
Astrazeneca Uk Limited is a live company located in cambridge, CB2 0AA with a Companies House number of 03674842. It operates in the activities of head offices sector, SIC Code 70100. Founded in November 1998, it's largest shareholder is astrazeneca intermediate holdings limited with a 100% stake. Astrazeneca Uk Limited is a mature, mega sized company, Pomanda has estimated its turnover at £14.4b with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Astrazeneca Uk Limited Health Check
Pomanda's financial health check has awarded Astrazeneca Uk Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 2 areas for improvement. Company Health Check FAQs
7 Strong
3 Regular
2 Weak
Size
annual sales of £14.4b, make it larger than the average company (£20.2m)
£14.4b - Astrazeneca Uk Limited
£20.2m - Industry AVG
Growth
3 year (CAGR) sales growth of 15%, show it is growing at a faster rate (7.4%)
15% - Astrazeneca Uk Limited
7.4% - Industry AVG
Production
with a gross margin of 45.5%, this company has a lower cost of product (33.7%)
45.5% - Astrazeneca Uk Limited
33.7% - Industry AVG
Profitability
an operating margin of 5.1% make it as profitable than the average company (5.9%)
5.1% - Astrazeneca Uk Limited
5.9% - Industry AVG
Employees
with 10057 employees, this is above the industry average (110)
10057 - Astrazeneca Uk Limited
110 - Industry AVG
Pay Structure
on an average salary of £129.3k, the company has a higher pay structure (£49.9k)
£129.3k - Astrazeneca Uk Limited
£49.9k - Industry AVG
Efficiency
resulting in sales per employee of £1.4m, this is more efficient (£204.7k)
£1.4m - Astrazeneca Uk Limited
£204.7k - Industry AVG
Debtor Days
it gets paid by customers after 9 days, this is earlier than average (45 days)
9 days - Astrazeneca Uk Limited
45 days - Industry AVG
Creditor Days
its suppliers are paid after 41 days, this is close to average (42 days)
41 days - Astrazeneca Uk Limited
42 days - Industry AVG
Stock Days
it holds stock equivalent to 43 days, this is in line with average (48 days)
43 days - Astrazeneca Uk Limited
48 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (15 weeks)
0 weeks - Astrazeneca Uk Limited
15 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 28.2%, this is a lower level of debt than the average (55.6%)
28.2% - Astrazeneca Uk Limited
55.6% - Industry AVG
ASTRAZENECA UK LIMITED financials
Astrazeneca Uk Limited's latest turnover from December 2023 is £14.4 billion and the company has net assets of £15.2 billion. According to their latest financial statements, Astrazeneca Uk Limited has 10,057 employees and maintains cash reserves of £13 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 14,403,000,000 | 11,933,000,000 | 10,303,000,000 | 9,350,000,000 | 7,950,000,000 | 6,803,000,000 | 5,392,000,000 | 6,851,000,000 | 5,091,000,000 | 4,178,000,000 | 4,471,000,000 | 5,527,000,000 | 7,495,000,000 | 7,638,000,000 | 6,721,000,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 7,847,000,000 | 6,490,000,000 | 6,465,000,000 | 5,870,000,000 | 5,231,000,000 | 4,209,000,000 | 3,613,000,000 | 4,124,000,000 | 3,079,000,000 | 2,379,000,000 | 2,670,000,000 | 3,335,000,000 | 3,740,000,000 | 3,490,000,000 | 2,574,000,000 |
| Gross Profit | 6,556,000,000 | 5,443,000,000 | 3,838,000,000 | 3,480,000,000 | 2,719,000,000 | 2,594,000,000 | 1,779,000,000 | 2,727,000,000 | 2,012,000,000 | 1,799,000,000 | 1,801,000,000 | 2,192,000,000 | 3,755,000,000 | 4,148,000,000 | 4,147,000,000 |
| Admin Expenses | 5,818,000,000 | 4,206,000,000 | 3,298,000,000 | 2,778,000,000 | 2,021,000,000 | 2,040,000,000 | 1,864,000,000 | 2,144,000,000 | 1,873,000,000 | 1,382,000,000 | 1,424,000,000 | 1,582,000,000 | 2,370,000,000 | 1,865,000,000 | 1,870,000,000 |
| Operating Profit | 738,000,000 | 1,237,000,000 | 540,000,000 | 702,000,000 | 698,000,000 | 554,000,000 | -85,000,000 | 583,000,000 | 139,000,000 | 417,000,000 | 377,000,000 | 610,000,000 | 1,385,000,000 | 2,283,000,000 | 2,277,000,000 |
| Interest Payable | 118,000,000 | 34,000,000 | 49,000,000 | 55,000,000 | 96,000,000 | 114,000,000 | 123,000,000 | 146,000,000 | 190,000,000 | 318,000,000 | 68,000,000 | 49,000,000 | 60,000,000 | 88,000,000 | 101,000,000 |
| Interest Receivable | 111,000,000 | 26,000,000 | 22,000,000 | 26,000,000 | 44,000,000 | 29,000,000 | 15,000,000 | 14,000,000 | 19,000,000 | 200,000,000 | 18,000,000 | 16,000,000 | 10,000,000 | 24,000,000 | 12,000,000 |
| Pre-Tax Profit | 10,957,000,000 | 2,682,000,000 | 2,015,000,000 | 1,385,000,000 | 8,366,000,000 | 1,624,000,000 | 973,000,000 | 5,997,000,000 | 179,000,000 | 3,749,000,000 | 4,258,000,000 | 9,714,000,000 | 3,246,000,000 | 2,219,000,000 | 2,188,000,000 |
| Tax | 15,000,000 | 121,000,000 | -17,000,000 | -98,000,000 | -101,000,000 | 12,000,000 | 2,000,000 | -85,000,000 | -43,000,000 | -15,000,000 | 32,000,000 | -122,000,000 | -470,000,000 | -581,000,000 | -419,000,000 |
| Profit After Tax | 10,972,000,000 | 2,803,000,000 | 1,998,000,000 | 1,287,000,000 | 8,265,000,000 | 1,636,000,000 | 975,000,000 | 5,912,000,000 | 136,000,000 | 3,734,000,000 | 4,290,000,000 | 9,592,000,000 | 2,776,000,000 | 1,638,000,000 | 1,769,000,000 |
| Dividends Paid | 11,062,000,000 | 400,000,000 | 765,000,000 | 1,770,000,000 | 6,444,000,000 | 200,000,000 | 2,475,000,000 | 2,977,000,000 | 1,177,000,000 | 1,519,000,000 | 3,930,000,000 | 9,135,000,000 | 1,910,000,000 | 1,350,000,000 | 1,740,000,000 |
| Retained Profit | -90,000,000 | 2,403,000,000 | 1,233,000,000 | -483,000,000 | 1,821,000,000 | 1,436,000,000 | -1,500,000,000 | 2,935,000,000 | -1,041,000,000 | 2,215,000,000 | 360,000,000 | 457,000,000 | 866,000,000 | 288,000,000 | 29,000,000 |
| Employee Costs | 1,300,000,000 | 1,207,000,000 | 982,000,000 | 787,000,000 | 758,000,000 | 712,000,000 | 703,000,000 | 661,000,000 | 702,000,000 | 546,000,000 | 748,000,000 | 750,000,000 | 715,000,000 | 769,000,000 | 690,000,000 |
| Number Of Employees | 10,057 | 9,105 | 8,185 | 7,173 | 6,619 | 6,468 | 6,195 | 6,451 | 6,518 | 6,541 | 6,692 | 7,352 | 8,151 | 9,364 | 9,944 |
| EBITDA* | 1,242,000,000 | 1,619,000,000 | 861,000,000 | 1,034,000,000 | 960,000,000 | 968,000,000 | 186,000,000 | 677,000,000 | 419,000,000 | 657,000,000 | 649,000,000 | 815,000,000 | 1,698,000,000 | 2,562,000,000 | 2,474,000,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,620,000,000 | 1,508,000,000 | 6,512,000,000 | 6,327,000,000 | 1,144,000,000 | 920,000,000 | 819,000,000 | 685,000,000 | 597,000,000 | 480,000,000 | 716,000,000 | 798,000,000 | 856,000,000 | 1,011,000,000 | 1,130,000,000 |
| Intangible Assets | 9,130,000,000 | 6,759,000,000 | 4,789,000,000 | 5,148,000,000 | 4,700,000,000 | 3,685,000,000 | 4,088,000,000 | 3,901,000,000 | 4,240,000,000 | 3,906,000,000 | 2,608,000,000 | 2,627,000,000 | 2,662,000,000 | 2,589,000,000 | 2,568,000,000 |
| Investments & Other | 5,098,000,000 | 4,995,000,000 | 4,634,000,000 | 4,634,000,000 | 4,652,000,000 | 5,074,000,000 | 5,153,000,000 | 5,312,000,000 | 5,789,000,000 | 5,395,000,000 | 4,283,000,000 | 4,036,000,000 | 4,039,000,000 | 4,189,000,000 | 4,302,000,000 |
| Debtors (Due After 1 year) | 294,000,000 | 305,000,000 | 98,000,000 | 182,000,000 | 283,000,000 | 325,000,000 | 875,000,000 | 785,000,000 | |||||||
| Total Fixed Assets | 15,848,000,000 | 13,262,000,000 | 11,140,000,000 | 11,288,000,000 | 10,594,000,000 | 9,861,000,000 | 10,343,000,000 | 10,223,000,000 | 10,626,000,000 | 10,656,000,000 | 8,392,000,000 | 7,461,000,000 | 7,557,000,000 | 7,789,000,000 | 8,000,000,000 |
| Stock & work in progress | 936,000,000 | 705,000,000 | 548,000,000 | 770,000,000 | 609,000,000 | 757,000,000 | 661,000,000 | 858,000,000 | 583,000,000 | 500,000,000 | 434,000,000 | 584,000,000 | 658,000,000 | 564,000,000 | 558,000,000 |
| Trade Debtors | 387,000,000 | 238,000,000 | 241,000,000 | 282,000,000 | 257,000,000 | 328,000,000 | 324,000,000 | 286,000,000 | 289,000,000 | 376,000,000 | 375,000,000 | 370,000,000 | 386,000,000 | 342,000,000 | 295,000,000 |
| Group Debtors | 3,046,000,000 | 7,348,000,000 | 6,434,000,000 | 5,191,000,000 | 5,623,000,000 | 3,402,000,000 | 2,733,000,000 | 3,771,000,000 | 1,067,000,000 | 1,854,000,000 | 1,156,000,000 | 1,126,000,000 | 1,032,000,000 | 450,000,000 | 361,000,000 |
| Misc Debtors | 987,000,000 | 975,000,000 | 796,000,000 | 671,000,000 | 609,000,000 | 932,000,000 | 681,000,000 | 519,000,000 | 486,000,000 | 524,000,000 | 524,000,000 | 150,000,000 | 155,000,000 | 574,000,000 | 595,000,000 |
| Cash | 13,000,000 | 6,000,000 | 3,000,000 | 12,000,000 | 7,000,000 | 11,000,000 | 1,000,000 | 321,000,000 | 315,000,000 | 502,000,000 | 481,000,000 | 486,000,000 | 213,000,000 | 258,000,000 | 30,000,000 |
| misc current assets | 78,000,000 | ||||||||||||||
| total current assets | 5,369,000,000 | 9,272,000,000 | 8,364,000,000 | 6,926,000,000 | 7,105,000,000 | 5,430,000,000 | 4,400,000,000 | 5,755,000,000 | 2,740,000,000 | 3,756,000,000 | 2,970,000,000 | 2,716,000,000 | 2,444,000,000 | 2,188,000,000 | 1,839,000,000 |
| total assets | 21,217,000,000 | 22,534,000,000 | 19,504,000,000 | 18,214,000,000 | 17,699,000,000 | 15,291,000,000 | 14,743,000,000 | 15,978,000,000 | 13,366,000,000 | 14,412,000,000 | 11,362,000,000 | 10,177,000,000 | 10,001,000,000 | 9,977,000,000 | 9,839,000,000 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 902,000,000 | 745,000,000 | 783,000,000 | 604,000,000 | 519,000,000 | 434,000,000 | 910,000,000 | 773,000,000 | 877,000,000 | 776,000,000 | 687,000,000 | 586,000,000 | 591,000,000 | 557,000,000 | 500,000,000 |
| Group/Directors Accounts | 1,911,000,000 | 2,812,000,000 | 1,679,000,000 | 1,506,000,000 | 2,197,000,000 | 1,515,000,000 | 1,746,000,000 | 1,564,000,000 | 1,399,000,000 | 1,828,000,000 | 1,740,000,000 | 2,237,000,000 | 1,956,000,000 | ||
| other short term finances | 104,000,000 | 16,000,000 | 49,000,000 | ||||||||||||
| hp & lease commitments | 12,000,000 | 14,000,000 | 15,000,000 | 16,000,000 | 16,000,000 | ||||||||||
| other current liabilities | 1,634,000,000 | 1,708,000,000 | 4,473,000,000 | 4,365,000,000 | 1,816,000,000 | 1,354,000,000 | 740,000,000 | 1,126,000,000 | 1,010,000,000 | 849,000,000 | 603,000,000 | 406,000,000 | 508,000,000 | 660,000,000 | 820,000,000 |
| total current liabilities | 4,459,000,000 | 5,279,000,000 | 5,375,000,000 | 5,001,000,000 | 4,079,000,000 | 3,294,000,000 | 3,847,000,000 | 3,414,000,000 | 3,633,000,000 | 3,189,000,000 | 2,689,000,000 | 2,820,000,000 | 2,839,000,000 | 3,454,000,000 | 3,276,000,000 |
| loans | 854,000,000 | 1,024,000,000 | 501,000,000 | 348,000,000 | 431,000,000 | 439,000,000 | 347,000,000 | 347,000,000 | 347,000,000 | 347,000,000 | 347,000,000 | 347,000,000 | 347,000,000 | ||
| hp & lease commitments | 58,000,000 | 59,000,000 | 62,000,000 | ||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | 1,487,000,000 | 1,681,000,000 | 203,000,000 | 423,000,000 | 305,000,000 | 659,000,000 | 802,000,000 | 950,000,000 | 1,090,000,000 | 1,167,000,000 | 851,000,000 | 70,000,000 | 67,000,000 | 68,000,000 | 66,000,000 |
| provisions | 39,000,000 | 102,000,000 | 984,000,000 | 1,900,000,000 | 47,000,000 | 43,000,000 | 44,000,000 | 52,000,000 | 94,000,000 | 194,000,000 | 283,000,000 | 250,000,000 | 309,000,000 | 369,000,000 | 382,000,000 |
| total long term liabilities | 1,526,000,000 | 1,783,000,000 | 1,122,000,000 | 1,885,000,000 | 1,765,000,000 | 1,884,000,000 | 2,229,000,000 | 2,240,000,000 | 2,195,000,000 | 2,691,000,000 | 2,319,000,000 | 1,091,000,000 | 1,368,000,000 | 1,438,000,000 | 1,757,000,000 |
| total liabilities | 5,985,000,000 | 7,062,000,000 | 6,497,000,000 | 6,886,000,000 | 5,844,000,000 | 5,178,000,000 | 6,076,000,000 | 5,654,000,000 | 5,828,000,000 | 5,880,000,000 | 5,008,000,000 | 3,911,000,000 | 4,207,000,000 | 4,892,000,000 | 5,033,000,000 |
| net assets | 15,232,000,000 | 15,472,000,000 | 13,007,000,000 | 11,328,000,000 | 11,855,000,000 | 10,113,000,000 | 8,667,000,000 | 10,324,000,000 | 7,538,000,000 | 8,532,000,000 | 6,354,000,000 | 6,266,000,000 | 5,794,000,000 | 5,085,000,000 | 4,806,000,000 |
| total shareholders funds | 15,232,000,000 | 15,472,000,000 | 13,007,000,000 | 11,328,000,000 | 11,855,000,000 | 10,113,000,000 | 8,667,000,000 | 10,324,000,000 | 7,538,000,000 | 8,532,000,000 | 6,354,000,000 | 6,266,000,000 | 5,794,000,000 | 5,085,000,000 | 4,806,000,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 738,000,000 | 1,237,000,000 | 540,000,000 | 702,000,000 | 698,000,000 | 554,000,000 | -85,000,000 | 583,000,000 | 139,000,000 | 417,000,000 | 377,000,000 | 610,000,000 | 1,385,000,000 | 2,283,000,000 | 2,277,000,000 |
| Depreciation | 79,000,000 | 92,000,000 | 85,000,000 | 84,000,000 | 74,000,000 | 59,000,000 | 52,000,000 | 72,000,000 | 71,000,000 | 92,000,000 | 154,000,000 | 118,000,000 | 216,000,000 | 191,000,000 | 135,000,000 |
| Amortisation | 425,000,000 | 290,000,000 | 236,000,000 | 248,000,000 | 188,000,000 | 355,000,000 | 219,000,000 | 22,000,000 | 209,000,000 | 148,000,000 | 118,000,000 | 87,000,000 | 97,000,000 | 88,000,000 | 62,000,000 |
| Tax | 15,000,000 | 121,000,000 | -17,000,000 | -98,000,000 | -101,000,000 | 12,000,000 | 2,000,000 | -85,000,000 | -43,000,000 | -15,000,000 | 32,000,000 | -122,000,000 | -470,000,000 | -581,000,000 | -419,000,000 |
| Stock | 231,000,000 | 157,000,000 | -222,000,000 | 161,000,000 | -148,000,000 | 96,000,000 | -197,000,000 | 275,000,000 | 83,000,000 | 66,000,000 | -150,000,000 | -74,000,000 | 94,000,000 | 6,000,000 | 558,000,000 |
| Debtors | -4,141,000,000 | 796,000,000 | 1,316,000,000 | -138,000,000 | 1,743,000,000 | 823,000,000 | -880,000,000 | 3,059,000,000 | -1,787,000,000 | 789,000,000 | 1,194,000,000 | 73,000,000 | 207,000,000 | 115,000,000 | 1,251,000,000 |
| Creditors | 157,000,000 | -38,000,000 | 179,000,000 | 85,000,000 | 85,000,000 | -476,000,000 | 137,000,000 | -104,000,000 | 101,000,000 | 89,000,000 | 101,000,000 | -5,000,000 | 34,000,000 | 57,000,000 | 500,000,000 |
| Accruals and Deferred Income | -74,000,000 | -2,765,000,000 | 108,000,000 | 2,549,000,000 | 462,000,000 | 614,000,000 | -386,000,000 | 116,000,000 | 161,000,000 | 246,000,000 | 197,000,000 | -102,000,000 | -152,000,000 | -160,000,000 | 820,000,000 |
| Deferred Taxes & Provisions | -63,000,000 | -882,000,000 | -916,000,000 | 1,853,000,000 | 4,000,000 | -1,000,000 | -8,000,000 | -42,000,000 | -100,000,000 | -89,000,000 | 33,000,000 | -59,000,000 | -60,000,000 | -13,000,000 | 382,000,000 |
| Cash flow from operations | 5,187,000,000 | -2,898,000,000 | -879,000,000 | 5,400,000,000 | -185,000,000 | 198,000,000 | 1,008,000,000 | -2,772,000,000 | 2,242,000,000 | 33,000,000 | -32,000,000 | 528,000,000 | 749,000,000 | 1,744,000,000 | 1,948,000,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 103,000,000 | 361,000,000 | -18,000,000 | -422,000,000 | -79,000,000 | -159,000,000 | -477,000,000 | 394,000,000 | 1,112,000,000 | 247,000,000 | -3,000,000 | -150,000,000 | -113,000,000 | 4,302,000,000 | |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -901,000,000 | 2,812,000,000 | -1,679,000,000 | 173,000,000 | -691,000,000 | 682,000,000 | -231,000,000 | 182,000,000 | 165,000,000 | -429,000,000 | 88,000,000 | -497,000,000 | 281,000,000 | 1,956,000,000 | |
| Other Short Term Loans | -104,000,000 | 88,000,000 | -33,000,000 | 49,000,000 | |||||||||||
| Long term loans | -854,000,000 | -170,000,000 | 523,000,000 | 153,000,000 | -83,000,000 | -8,000,000 | 92,000,000 | 347,000,000 | |||||||
| Hire Purchase and Lease Commitments | -2,000,000 | -59,000,000 | -2,000,000 | -3,000,000 | 78,000,000 | ||||||||||
| other long term liabilities | -194,000,000 | 1,478,000,000 | -220,000,000 | 118,000,000 | -354,000,000 | -143,000,000 | -148,000,000 | -140,000,000 | -77,000,000 | 316,000,000 | 781,000,000 | 3,000,000 | -1,000,000 | 2,000,000 | 66,000,000 |
| share issue | |||||||||||||||
| interest | -7,000,000 | -8,000,000 | -27,000,000 | -29,000,000 | -52,000,000 | -85,000,000 | -108,000,000 | -132,000,000 | -171,000,000 | -118,000,000 | -50,000,000 | -33,000,000 | -50,000,000 | -64,000,000 | -89,000,000 |
| cash flow from financing | -1,254,000,000 | 3,327,000,000 | 115,000,000 | -1,147,000,000 | -32,000,000 | -992,000,000 | 261,000,000 | -560,000,000 | -19,000,000 | 326,000,000 | 30,000,000 | 73,000,000 | -705,000,000 | 210,000,000 | 7,057,000,000 |
| cash and cash equivalents | |||||||||||||||
| cash | 7,000,000 | 3,000,000 | -9,000,000 | 5,000,000 | -4,000,000 | 10,000,000 | -320,000,000 | 6,000,000 | -187,000,000 | 21,000,000 | -5,000,000 | 273,000,000 | -45,000,000 | 228,000,000 | 30,000,000 |
| overdraft | |||||||||||||||
| change in cash | 7,000,000 | 3,000,000 | -9,000,000 | 5,000,000 | -4,000,000 | 10,000,000 | -320,000,000 | 6,000,000 | -187,000,000 | 21,000,000 | -5,000,000 | 273,000,000 | -45,000,000 | 228,000,000 | 30,000,000 |
astrazeneca uk limited Credit Report and Business Information
Astrazeneca Uk Limited Competitor Analysis
Perform a competitor analysis for astrazeneca uk limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mega companies, companies in CB2 area or any other competitors across 12 key performance metrics.
astrazeneca uk limited Ownership
ASTRAZENECA UK LIMITED group structure
Astrazeneca Uk Limited has 15 subsidiary companies.
Ultimate parent company
2 parents
ASTRAZENECA UK LIMITED
03674842
15 subsidiaries
astrazeneca uk limited directors
Astrazeneca Uk Limited currently has 13 directors. The longest serving directors include Mr Pascal Soriot (Oct 2012) and Mr Iain Collins (May 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Pascal Soriot | United Kingdom | 65 years | Oct 2012 | - | Director |
| Mr Iain Collins | United Kingdom | 54 years | May 2017 | - | Director |
| Aradhana Sarin | United Kingdom | 50 years | Aug 2021 | - | Director |
| Aradhana Sarin | United Kingdom | 50 years | Aug 2021 | - | Director |
| Susan Galbraith | United Kingdom | 59 years | Jun 2024 | - | Director |
| Ms Sally Sambrook | United Kingdom | 52 years | Jun 2024 | - | Director |
| Ms Christine Stephens | United Kingdom | 53 years | Jun 2024 | - | Director |
| Mr Rudi Dobber | United Kingdom | 60 years | Jun 2024 | - | Director |
| Mr Pablo Panella | United Kingdom | 53 years | Jun 2024 | - | Director |
| Ms Caterina Brindicci | United Kingdom | 49 years | Jun 2024 | - | Director |
P&L
December 2023turnover
14.4b
+21%
operating profit
738m
-40%
gross margin
45.6%
-0.21%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
15.2b
-0.02%
total assets
21.2b
-0.06%
cash
13m
+1.17%
net assets
Total assets minus all liabilities
astrazeneca uk limited company details
company number
03674842
Type
Private limited with Share Capital
industry
70100 - Activities of head offices
incorporation date
November 1998
age
27
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
astrazeneca pharma limited (August 1999)
astrazeneca limited (April 1999)
accountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
1 francis crick avenue, cambridge biomedical campus, cambridge, CB2 0AA
Bank
-
Legal Advisor
-
astrazeneca uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 5 charges/mortgages relating to astrazeneca uk limited. Currently there are 4 open charges and 1 have been satisfied in the past.
astrazeneca uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ASTRAZENECA UK LIMITED. This can take several minutes, an email will notify you when this has completed.
astrazeneca uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
